GoodRx Holdings, Inc. (NASDAQ: GDRX) saw its stock soar 8.58% in pre-market trading on Thursday, following the release of a compelling study by GoodRx Research. The study shed light on the significant limitations of Medicare drug coverage compared to employer-sponsored plans, underscoring the potential value of GoodRx's services in the growing retiree market.

The GoodRx Research study revealed that the average Medicare plan excludes 44% of medications, a stark contrast to the 21% exclusion rate in average commercial insurance plans. Furthermore, nearly half of the drugs covered by Medicare plans are subject to restrictions such as prior authorization or step therapy. These findings suggest a substantial market opportunity for GoodRx's prescription discount services among the expanding population of Medicare-eligible retirees.

The timing of this study is particularly significant, as approximately 11,000 baby boomers are turning 65 each day. As retirees face more limited drug coverage and potentially higher out-of-pocket costs under Medicare, GoodRx's platform could become an increasingly valuable tool for finding affordable medication options. Investors appear to be reacting positively to this potential growth catalyst, driving the stock's pre-market surge.